A newly published "review" article:
🔹️Fully funded and written with company support
🔹️Includes company employees as co-authors
🔹️Medical writing outsourced and paid for
🎗 Yet declares: "no conflicts of interest"
🫣And it's published in one of the highest-impact journals in the field
How did we get here?
It’s time for a serious conversation about the blurred lines in academic publishing🧐
3) With accelerated approval there is always a trade off between having active drugs available for patients with unmet need who have a life threatening illness versus the risk that some drugs without adequate clinical benefit or with risks slipping through (eg. Pano, melflufen)
@Leo_ReapDO@majorajay @AaronGoodman33 Treated 2 such patients. Usually can drag feet if not symptomatic and collaborate with high risk Ob Doc. Used Vinblastine and Methyl Pred as needed Q 2-3 weeks in third Trimester and did auto-HCT
@graham74GC@majorajay Not very many patients have long term response especially for post CAR T relapse. Would fixed vs continuous dosing matter in initial decision making.
@Transplant_Doc@Myeloma_Doc Also at global scale much more affordable treatment than most modern therapies which assume patients would be happy to come to infusion center regularly in addition to financial burden.
The British empire caused 165 million deaths in India in 40 years:
A new study found that British colonialism caused approximately 165 million deaths in India from 1880 to 1920, while stealing trillions of dollars of wealth
https://t.co/X6Ri5aH6lM